MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA

Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in eczema patients. K201 was very well tolerated.

K201 is a topical and steroid-free treatment of mild to moderate atopic eczema which is designed to alleviate itching and reduce dryness as well as prevent bacterial- and fungal infections, without risk for development of resistance. The phase II clinical study was a comparative study where patients were treated twice daily during 4 weeks with either K201 or a moisturising pharmaceutical. The patients were evaluated both clinically and by a set of objective variables. Atopic eczema affects approximately 15-20 percent of all children and 2-3 percent of the adult population "We are pleased with the results of the phase II study, which indicates that K201 can provide significant benefits in the treatment of atopic eczema", says Moberg Derma's CEO, Peter Wolpert. Moberg Derma is developing a portfolio of medical products for skin disorders based on the company’s patented technology as well as acquired projects. This spring the company announced its first commercial agreement and it intends to expand its existing product portfolio through in-house development as well as through further acquisitions.

Tags: